REG - Scancell Hlds - Scancell to attend upcoming conferences

Scancell HoldingsAnnouncement

31/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe5440Qa&default-theme=true

RNS Number : 5440Q  Scancell Holdings Plc  31 May 2024

31 May 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell Announces its Attendance at Upcoming Conferences

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, today confirms that it will attend and present at the
upcoming conferences listed below. Presentations at these high-profile
conferences follow the significant recent progress that Scancell has made in
developing its pipeline of innovative immunotherapies to address unmet needs
in cancer.

 

·      BIO International Convention (https://convention.bio.org/) ,
taking place in San Diego, CA from 3-6 June.

Mandeep Sehmi, Head of Business Development, will be attending the conference.

 

·      Antibody Engineering & Therapeutics Europe
(https://informaconnect.com/antibody-engineering-europe/) , taking place in
London, UK from 4-6 June.

Bubacarr Gibril Kaira, Antibody Research Scientist at Scancell, will be
presenting at the conference.

Mireille Vankemmelbeke, Principal Scientist at Scancell, will also be
attending.

Session Title: Fc Engineering and Fc Receptor Function

Title: Unlocking the Unique Potential of AvidiMAb® in Clustering and
Signalling

Date and Time: Tuesday 4(th) June at 5:15pm BST

 

If you would like to arrange a meeting with management, please contact
commercial.enquiries@scancell.co.uk
(mailto:commercial.enquiries@scancell.co.uk) .

 

-ENDS-

 

 For further information, please contact:

 Scancell Holdings plc                                                +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)  +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/Ben Good
 Nick Harland (Corporate Broking)

 WG Partners LLP (Joint Broker)                                       +44 (0) 20 3705 9330

 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                           +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 ICR Consilium                                                        +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville                        scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope® and
ImmunoBody® ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab® ) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab® ).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKKBPABKDCPN